New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
12:25 EDTCOV, WMGI, SNN, SYK, NUVA, ARTC, ZMH, JNJ, GMEDAnother bidder may emerge for ArthroCare, says William Blair
William Blair says it would not be surprised to see another bidder emerge for ArthroCare (ARTC). The firm lists Johnson & Johnson (JNJ) and Stryker (SYK)) as the most likely to submit a competing bid to Smith & Nephew's (SNN), and notes Biomet, Zimmer (ZMH) and Covidien (COV) could also have interest in the company. Should the deal for ArthroCare close as currently contemplated, William Blair thinks peers Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI) could be takeover targets.
News For ARTC;SNN;GMED;NUVA;WMGI;JNJ;SYK;COV;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
13:34 EDTSYKStryker shares look inexpensive, should continue to rise, Barron's says
Despite rising more than 30% over the past year, shares of Stryker still have plenty of upside potential, Barron's reports. The company sports industry-leading organic sales, a strong balance sheet, and is trading at a discount to the broader medical device industry, all of which should push shares higher, Barron's adds. Reference Link
11:08 EDTJNJJohnson & Johnson receives positive CHMP opinion to extend Velcade indication
Subscribe for More Information
10:17 EDTWMGIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:36 EDTWMGIWright Medical initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 17, 2014
09:04 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
08:06 EDTJNJInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information
06:17 EDTSNNWPP PLC confirms Roberto Quarta as chairman-designate
WPP plc (WPPGY) announces the appointment of Roberto Quarta to its Board as a non-executive director and Chairman-designate. He will join the Board on January 1, 2015 and will offer himself for re-election at the company’s Annual General Meeting to be held in June 2015. Subject to his re-election, he will be appointed Chairman to succeed Philip Lader, who joined the Board as Chairman in 2001. Roberto Quarta is Chairman of Smith & Nephew plc (SNN), a FTSE 100 global medical technology company, and Chairman of IMI plc, a FTSE 250 engineering business. He is also a partner at the private equity firm Clayton, Dubilier & Rice and a non-executive director at Spie SA. The transition in the Chairman’s role will occur, if Quarta has resigned from the IMI Board as anticipated, immediately at the close of WPP’s June AGM or thereafter upon such resignation.
05:33 EDTSNNSmith & Nephew says study shows incisions had fewer complications with PICO NPWT
Smith & Nephew announces that data from an international, multicentre-study presented at the Aesthetic Surgery of the Breast Symposium, has shown significantly fewer wound healing complications associated with breast reduction surgery, through the post-operative application of PICO Negative Pressure Wound Therapy, or NPWT. 200 bilateral breast reduction patients were observed across six leading centres PICO was used as an incision management system and compared to the standard post–operative wound care procedure. The primary analysis shows significantly fewer healing complications for PICO compared to standard care, and a 38% relative reduction in surgical dehiscence from 26.4% to 16.2%.
December 16, 2014
07:20 EDTJNJGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
07:32 EDTNUVAStifel to hold a bus tour
Subscribe for More Information
December 12, 2014
14:01 EDTJNJGenOn Energy to receive $3M milestone payment in Janssen collaboration
Genmab announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech (JNJ), triggering a $3M payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Today's news will not impact Genmab's 2014 financial guidance.
December 9, 2014
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
12:42 EDTSYKStryker resolves government investigation of OtisMed matter
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use